Last Price
9.99
Today's Change
-0.35 (3.38%)
Day's Change
9.70 - 11.10
Trading Volume
5,764,022
Market Cap
325 Million
Shares Outstanding
32 Million
Avg Volume
1,563,111
Avg Price (50 Days)
4.60
Avg Price (200 Days)
4.97
PE Ratio
-11.22
EPS
-0.89
Earnings Announcement
12-Nov-2024
Previous Close
10.34
Open
9.96
Day's Range
9.7 - 11.1
Year Range
2.68 - 12.87
Trading Volume
5,776,970
1 Day Change
-3.38%
5 Day Change
100.20%
1 Month Change
104.29%
3 Month Change
115.77%
6 Month Change
58.32%
Ytd Change
95.12%
1 Year Change
74.65%
3 Year Change
122.99%
5 Year Change
249.30%
10 Year Change
-73.50%
Max Change
-97.78%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.